For the quarter ending 2025-09-30, BGLC has $7,621,228 in assets. $804,966 in debts.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and bank balances | 1,153,121 | 814,179 | ||
| Fixed deposits placed with financial institutions (including 1,537,561 and 1,490,461 of fixed deposits with original maturities more than 3 months as of september 30, 2025 and december 31, 2024 respectively) | 1,741,532 | 2,244,699 | ||
| Trade receivables, net of allowance for credit losses of 671,777 and 517,877 as of september 30, 2025 and december 31, 2024 respectively (including 25,760 and 47,272 of trade receivables from related parties as of september 30, 2025 and december 31, 2024 respectively) | 1,522,158 | 1,852,085 | ||
| Other receivables, deposits and prepayments | 98,903 | 151,269 | ||
| Tax recoverable | 103,640 | 101,471 | ||
| Inventories (including goods in transit of 190,588 and 188,797 as of september 30, 2025 and december 31, 2024 respectively) | 1,007,448 | 1,215,623 | ||
| Total current assets | 5,626,802 | 6,379,326 | ||
| Operating lease right-of-use assets | 186,082 | 200,284 | ||
| Property, plant and equipment, net | 1,570,584 | 1,592,907 | ||
| Investments in equity securities | 237,760 | 1,248,688 | ||
| Total non-current assets | 1,994,426 | 3,041,879 | ||
| Total assets | 7,621,228 | 9,421,205 | ||
| Trade payables | 184,600 | 1,367,535 | ||
| Other payables and accrued liabilities | 375,380 | 307,340 | ||
| Current portion of operating lease liabilities | 56,803 | 55,809 | ||
| Advance payment from customer | 11,264 | 11,348 | ||
| Amount owing to directors | 49,976 | 15,789 | ||
| Total current liabilities | 678,023 | 1,757,821 | ||
| Non-current portion of operating lease liabilities | 126,943 | 141,347 | ||
| Deferred tax liabilities | 0 | 0 | ||
| Total non-current liabilities | 126,943 | 141,347 | ||
| Total liabilities | 804,966 | 1,899,168 | ||
| As at september 30, 2025, common stock, no par value 300,000,000 shares authorized and 1,796,597 shares outstanding, and preferred stock, no par value 30,000,000 shares authorized and no shares outstanding. as at december 31, 2024, common stock, no par value 300,000,000 shares authorized and 1,796,766 shares outstanding, and preferred stock, no par value 30,000,000 share authorized and no shares outstanding (on a post-reverse stock split basis) | 17,331,810 | 17,331,810 | ||
| Additional paid in capital | -5,011,891 | -5,011,891 | ||
| Accumulated deficit | -5,391,110 | -4,682,119 | ||
| Accumulated other comprehensive losses | -112,547 | -115,763 | ||
| Total stockholders' equity | 6,816,262 | 7,522,037 | ||
| Total liabilities and stockholders' equity | 7,621,228 | 9,421,205 | ||
BioNexus Gene Lab Corp (BGLC)
BioNexus Gene Lab Corp (BGLC)